惠倫晶體(300460.SZ):終止籌劃公司控制權變更事項
格隆匯8月2日丨惠倫晶體(300460.SZ)公佈,此前披露,公司”)的控股股東新疆惠倫股權投資合夥企業(有限合夥)(簡稱“新疆惠倫”),於2023年11月30日與黃天歌先生(以下簡稱受讓方)簽署了《股份轉讓意向協議》,擬將其持有的公司28,080,425股普通股股份(佔公司股本總額的10%,以下簡稱“標的股份”)轉讓給受讓方及其一致行動人(以下簡稱“本次股份轉讓”)。
公司今日收到控股股東新疆惠倫的通知,由於資本市場環境發生變化,新疆惠倫與黃天歌先生於2024年8月2日簽署了《終止協議》,約定自《終止協議》簽訂生效之日起,《股份轉讓意向協議》終止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.